MCID: OVR012
MIFTS: 42

Ovarian Serous Cystadenocarcinoma malady

Summaries for Ovarian Serous Cystadenocarcinoma

About this section


Disease Ontology:9 An ovary serous adenocarcinoma that has material basis in glandular epithelium, in which cystic accumulations of retained secretions are formed.

MalaCards based summary: Ovarian Serous Cystadenocarcinoma, also known as cystadenoma, serous, is related to cystadenocarcinoma and adenofibroma. An important gene associated with Ovarian Serous Cystadenocarcinoma is BIRC5 (baculoviral IAP repeat containing 5), and among its related pathways are TP53 network and Vinka Alkaloid Pathway, Pharmacokinetics. The compounds idoxifene and estradiol benzoate have been mentioned in the context of this disorder. Affiliated tissues include ovary and breast, and related mouse phenotypes are hearing/vestibular/ear and adipose tissue.

Aliases & Classifications for Ovarian Serous Cystadenocarcinoma

About this section
Sources:
9Disease Ontology, 11DISEASES, 43Novoseek, 60UMLS, 38NCIt
See all sources

Ovarian Serous Cystadenocarcinoma, Aliases & Descriptions:

Name: Ovarian Serous Cystadenocarcinoma 9 11 43 60
Cystadenoma, Serous 60
 
Cystadenoma Serous 43
Serous Cystadenoma 9


External Ids:

Disease Ontology9 DOID:5746
NCIt38 C7978

Related Diseases for Ovarian Serous Cystadenocarcinoma

About this section

Diseases related to Ovarian Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 114)
idRelated DiseaseScoreTop Affiliating Genes
1cystadenocarcinoma32.2MUC16
2adenofibroma31.0MUC16
3breast cancer30.4PGR, ESR1
4adenoma30.4BAX, BIRC5, ESR2, BCL2
5infertility30.2CYP19A1, ESR1, ESR2
6endometriosis29.7MUC16, ESR1, CYP19A1, VEGFA, ESR2, PGR
7leukemia29.7BAX, BIRC5, ESR2, FAS, AKT1, BCL2
8adenocarcinoma28.7AKT1, BCL2, BIRC5, BAX, FAS, MUC16
9cystadenoma11.2
10pancreatitis11.0
11pancreatic serous cystadenoma11.0
12serous cystadenocarcinoma10.9
13pericardial effusion10.5MUC16
14cerebral meningioma10.4PGR
15microcystic adenoma10.4
16ovarian disease10.3MUC16, CYP19A1
17sertoli-leydig cell tumor10.3
18portal hypertension10.3
19obstructive jaundice10.3
20endosalpingiosis10.3
21leydig cell tumor10.3
22struma ovarii10.3
23tuberculosis10.3
24plasma cell leukemia10.3
25ovarian cyst10.3ESR2, MUC16, CYP19A1
26estrogen excess10.2CYP19A1, PGR
27malignant pleural mesothelioma10.2MUC16, BIRC5
28sertoli cell tumor10.2CYP19A1, PGR
29endocrine gland cancer10.2CYP19A1, ESR1
30ovarian hyperstimulation syndrome10.2CYP19A1, VEGFA
31benign meningioma10.2BIRC5, PGR
32progesterone resistance10.2PGR, ESR1
33uterine sarcoma10.2CYP19A1, ESR1
34cutaneous t cell lymphoma10.2BAX, FAS, BIRC5
35von hippel-lindau syndrome10.1
36obesity10.1
37lipoma10.1
38hepatitis10.1
39islet cell tumor10.1
40pancreatic ductal adenocarcinoma10.1
41neuroendocrine carcinoma10.1
42fibroma10.1
43mucinous cystadenocarcinoma10.1
44splenic artery aneurysm10.1
45compartment syndrome10.1
46conjunctivitis10.1
47cystadenofibroma10.1
48mediastinitis10.1
49neuroendocrine tumor10.1
50peritonitis10.1

Graphical network of the top 20 diseases related to Ovarian Serous Cystadenocarcinoma:



Diseases related to ovarian serous cystadenocarcinoma

Symptoms for Ovarian Serous Cystadenocarcinoma

About this section

Drugs & Therapeutics for Ovarian Serous Cystadenocarcinoma

About this section

Drug clinical trials:

Search ClinicalTrials for Ovarian Serous Cystadenocarcinoma

Search NIH Clinical Center for Ovarian Serous Cystadenocarcinoma

Genetic Tests for Ovarian Serous Cystadenocarcinoma

About this section

Anatomical Context for Ovarian Serous Cystadenocarcinoma

About this section

MalaCards organs/tissues related to Ovarian Serous Cystadenocarcinoma:

31
Ovary, Breast

Animal Models for Ovarian Serous Cystadenocarcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Ovarian Serous Cystadenocarcinoma:

35 (show all 24)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053779.2CYP19A1, BCL2, ESR2, FAS, BAX
2MP:00053759.0CYP19A1, BCL2, AKT1, ESR1, ESR2
3MP:00053718.9ESR2, BAX, FAS, VEGFA, PGR, ESR1
4MP:00053708.9FAS, AKT1, ESR2, VEGFA, CYP19A1, ESR1
5MP:00028738.8BIRC5, AKT1, CYP19A1, VEGFA, PGR, ESR2
6MP:00053888.6BAX, BCL2, AKT1, ESR1, FAS, VEGFA
7MP:00020068.6BCL2, AKT1, FAS, ESR1, ESR2, PGR
8MP:00053678.3BAX, BCL2, VEGFA, FAS, ESR1, ESR2
9MP:00053908.0FAS, ESR1, ESR2, PGR, VEGFA, USP14
10MP:00053697.9ESR2, BCL2, AKT1, ESR1, PGR, VEGFA
11MP:00053977.9BAX, VEGFA, PGR, ESR2, ESR1, FAS
12MP:00053877.9BAX, BIRC5, BCL2, AKT1, FAS, CYP19A1
13MP:00107717.9AKT1, ESR2, BCL2, FAS, ESR1, PGR
14MP:00053807.9BIRC5, VEGFA, PGR, AKT1, ESR1, NANOG
15MP:00036317.8AKT1, CYP19A1, BAX, BCL2, USP14, FAS
16MP:00030127.8VEGFA, ESR1, USP2, PGR, NANOG, ESR2
17MP:00053787.8CYP19A1, VEGFA, BCL2, USP14, FAS, AKT1
18MP:00053857.8CYP19A1, VEGFA, BCL2, AKT1, FAS, ESR1
19MP:00053797.6USP2, ESR2, VEGFA, FAS, AKT1, BCL2
20MP:00053897.1BAX, CYP19A1, USP14, USP2, VEGFA, PGR
21MP:00053867.0CYP19A1, USP14, USP2, PGR, ESR2, ESR1
22MP:00053766.8BCL2, BIRC5, BAX, ESR2, USP14, AKT1
23MP:00107686.8ESR1, BAX, ESR2, FAS, AKT1, USP14
24MP:00053846.6BAX, CYP19A1, VEGFA, BCL2, BIRC5, AKT1

Publications for Ovarian Serous Cystadenocarcinoma

About this section

Articles related to Ovarian Serous Cystadenocarcinoma:

(show all 13)
idTitleAuthorsYear
1
Ovarian serous cystadenocarcinoma metastasising to the breast. (23445161)
2013
2
Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. (21266826)
2010
3
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. (18574502)
2008
4
Plasma cell leukemia with ovarian serous cystadenocarcinoma. (17883177)
2007
5
Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. (17553343)
2007
6
Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. (16793610)
2006
7
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. (11201519)
2001
8
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis. (11516810)
2001
9
Successful treatment of an advanced ovarian serous cystadenocarcinoma in pregnancy with cisplatin, adriamycin and cyclophosphamide (CAP) regimen. Case report. (10968352)
2000
10
Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. (9506768)
1998
11
Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. (2314830)
1990
12
Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). (3165255)
1988
13
Characterization of newly established cell line HUOA from a human ovarian serous cystadenocarcinoma. (3598277)
1987

Variations for Ovarian Serous Cystadenocarcinoma

About this section

Expression for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section
Search GEO for disease gene expression data for Ovarian Serous Cystadenocarcinoma.

Pathways for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section

Pathways related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 58)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
9.9BAX, BCL2
29.9BAX, BCL2
3
Show member pathways
IL-9 Signaling Pathway36
Development Thrombopoietin regulated cell processes58
IL-7 Signaling Pathway36
Immune response IL 9 signaling pathway58
9.8AKT1, BIRC5, BAX
49.8AKT1, BAX, BIRC5
59.7AKT1, ESR2, ESR1
69.7AKT1, ESR2, ESR1
7
Show member pathways
Development Ligand independent activation of ESR1 and ESR258
9.7ESR1, AKT1, ESR2
89.7PGR, CYP19A1, ESR2
9
Show member pathways
IL23-mediated signaling events36
Immune response IL 10 signaling pathway58
Angiopoietin receptor Tie2-mediated signaling36
Development PDGF signaling via STATs and NF kB58
Development Angiopoietin Tie2 signaling58
9.7BCL2, BIRC5, AKT1
109.7BCL2, AKT1, BIRC5
11
Show member pathways
9.7ESR1, ESR2, CYP19A1
12
Show member pathways
9.6BAX, BCL2, AKT1
139.6BAX, AKT1, BCL2
14
Show member pathways
9.6BCL2, BAX, AKT1
15
Show member pathways
9.6BAX, BCL2, AKT1
16
Show member pathways
Apoptosis and survival BAD phosphorylation58
Development Alpha 2 adrenergic receptor activation of ERK58
Chemotaxis CXCR4 signaling pathway58
9.6BCL2, BAX, AKT1
179.6AKT1, BCL2, BAX
18
Show member pathways
Prostate Cancer36
Integrated Cancer pathway36
Steroid Biosynthesis36
9.6AKT1, BCL2, BAX
199.6AKT1, BCL2, BAX
20
Show member pathways
Nuclear Receptors36
9.6PGR, ESR2, ESR1
21
Show member pathways
Cell cycle ESR1 regulation of G1 S transition58
Immune response MIF JAB1 signaling58
Cell cycle Cell cycle generic schema 58
9.6ESR1, PGR, AKT1
229.6BCL2, FAS, BAX
23
Show member pathways
9.6FAS, BCL2, BAX
249.6BCL2, AKT1, ESR1
25
Show member pathways
Development VEGF signaling via VEGFR2 generic cascades58
9.5AKT1, ESR1, VEGFA
269.5BCL2, AKT1, VEGFA
27
Show member pathways
Signal transduction PTEN pathway58
9.4AKT1, BIRC5, BCL2, BAX
289.4BAX, BIRC5, BCL2, AKT1
299.4BAX, FAS, BCL2, BIRC5
30
Show member pathways
Apoptosis and survival Apoptotic TNF family pathways58
9.4FAS, BAX, BIRC5, BCL2
31
Show member pathways
FAS pathway and Stress induction of HSP regulation36
Apoptosis and survival FAS signaling cascades58
Caspase cascade in apoptosis36
9.4BAX, AKT1, FAS, BCL2
32
Show member pathways
9.4FAS, AKT1, BCL2, BAX
33
Show member pathways
Apoptosis and survival TNFR1 signaling pathway58
TWEAK Signaling Pathway36
Apoptosis Modulation by HSP7036
HIV-1 Nef- Negative effector of Fas and TNF-alpha36
9.4BAX, BCL2, FAS, AKT1
34
Show member pathways
9.4BCL2, BAX, AKT1, FAS
359.3BAX, BCL2, ESR2, ESR1
36
Show member pathways
Cytoskeleton remodeling FAK signaling58
Development Endothelin 1 EDNRA transactivation of EGFR58
9.3AKT1, ESR1, ESR2, VEGFA
37
Show member pathways
Apoptosis Modulation and Signaling36
Apoptosis36
9.1BCL2, FAS, AKT1, BIRC5, BAX
38
Show member pathways
Toll-like receptor signaling pathway36
Regulation of toll-like receptor signaling pathway36
9.1BAX, BIRC5, BCL2, FAS, AKT1
39
Show member pathways
9.1BAX, BCL2, AKT1, BIRC5, FAS
40
Show member pathways
9.1ESR2, BIRC5, AKT1, BCL2, ESR1
41
Show member pathways
Prolactin Signaling Pathway36
Development Prolactin receptor signaling58
Leptin signaling pathway36
9.1ESR1, AKT1, BCL2, BAX, ESR2
429.0VEGFA, NANOG, ESR2
43
Show member pathways
Development EGFR signaling via PIP358
Development PDGF signaling via MAPK cascades58
Apoptosis and survival Anti apoptotic action of membrane bound ESR158
Signaling of Hepatocyte Growth Factor Receptor36
Development EGFR signaling via small GTPases58
Development Neurotrophin family signaling58
Apoptosis and survival NGF signaling pathway58
Apoptosis and survival Role of CDK5 in neuronal death and survival58
9.0ESR1, BAX, FAS, AKT1, BCL2
44
Show member pathways
9.0AKT1, VEGFA, BCL2, BAX, FAS
45
Show member pathways
8.9AKT1, ESR1, ESR2, NANOG
46
Show member pathways
DNA damage response (only ATM dependent)36
Wnt Signaling Pathway and Pluripotency36
8.8BAX, NANOG, BCL2, AKT1
478.8BAX, VEGFA, AKT1, FAS, BCL2, BIRC5
488.7BCL2, ESR1, BAX, AKT1, CYP19A1, VEGFA
498.4VEGFA, NANOG, AKT1, FAS, ESR1
508.4BCL2, ESR2, ESR1, FAS, BAX, VEGFA

Compounds for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section

Compounds related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 235)
idCompoundScoreTop Affiliating Genes
1idoxifene439.7PGR, ESR1, CYP19A1
2estradiol benzoate439.7ESR1, PGR, CYP19A1, ESR2
3nandrolone43 2410.7CYP19A1, PGR, ESR1, ESR2
4leuprolide acetate439.7ESR1, ESR2, PGR, CYP19A1
5anastrozole43 49 1211.6ESR1, PGR, CYP19A1, ESR2
6exemestane43 49 59 1212.6ESR1, CYP19A1, PGR, ESR2
7bisphenol a439.6PGR, CYP19A1, ESR2, ESR1
8lapatinib43 49 1211.6BIRC5, PGR, CYP19A1, ESR1
9clomiphene citrate439.6ESR2, ESR1, PGR, CYP19A1
103,3-diindolylmethane439.6BAX, BIRC5, ESR1, VEGFA
11hoechst 33342439.6BCL2, BIRC5, FAS, BAX
12toremifene43 1210.5CYP19A1, PGR, ESR1, FAS, ESR2
13fulvestrant43 49 28 1212.5ESR1, CYP19A1, PGR, ESR2
144-hydroxytamoxifen439.4CYP19A1, PGR, ESR2, ESR1, AKT1
15letrozole43 49 59 1212.4ESR1, ESR2, PGR, CYP19A1
16indole-3-carbinol439.3CYP19A1, ESR1, AKT1, BIRC5, BCL2, BAX
17gefitinib43 49 1211.2BIRC5, AKT1, ESR1, ESR2, VEGFA, CYP19A1
18adriamycin439.2PGR, FAS, AKT1, BAX, BCL2, BIRC5
19celecoxib43 59 28 49 24 1214.2BCL2, AKT1, VEGFA, CYP19A1, BIRC5, BAX
20progestin439.2PGR, VEGFA, ESR2, ESR1, CYP19A1
21gemcitabine43 49 1211.2BAX, BCL2, AKT1, VEGFA, CYP19A1, BIRC5
22thymidylate439.1FAS, ESR2, BIRC5, BAX, VEGFA, BCL2
23trastuzumab43 49 1211.1CYP19A1, VEGFA, PGR, ESR1, FAS, BIRC5
24egcg439.1BAX, VEGFA, ESR2, FAS, BCL2, BIRC5
25taxane439.1ESR1, BCL2, PGR, CYP19A1, VEGFA, BIRC5
26levonorgestrel43 59 28 1212.1ESR1, PGR, CYP19A1, ESR2
27etoposide43 49 59 1212.0BAX, BIRC5, BCL2, FAS, ESR2, AKT1
28mifepristone43 28 59 1211.9CYP19A1, VEGFA, PGR, ESR2, ESR1, BAX
29arsenite43 249.9AKT1, VEGFA, FAS, PGR, BAX, BIRC5
30mg 13243 599.9BIRC5, BCL2, BAX, VEGFA, AKT1, FAS
31docetaxel43 49 59 1211.8CYP19A1, BAX, PGR, BIRC5, BCL2, ESR1
32ly294002438.8ESR1, FAS, AKT1, VEGFA, BCL2, BIRC5
33sb 20358043 599.8BAX, BCL2, AKT1, FAS, VEGFA, BIRC5
34cyclophosphamide43 49 1210.7BCL2, MUC16, ESR1, PGR, VEGFA, CYP19A1
35n acetylcysteine438.7FAS, VEGFA, AKT1, BAX, BCL2, BIRC5
36actinomycin d438.6BCL2, BIRC5, BAX, ESR1, VEGFA, ESR2
37resveratrol43 59 24 1211.6VEGFA, PGR, ESR2, ESR1, FAS, BCL2
385fluorouracil438.5BCL2, BAX, BIRC5, CYP19A1, ESR1, FAS
39testosterone43 59 24 1211.5FAS, MUC16, AKT1, BIRC5, ESR1, ESR2
40cisplatin43 49 59 1211.4MUC16, FAS, AKT1, BCL2, ESR1, BIRC5
41retinoic acid43 249.4BIRC5, BAX, BCL2, AKT1, FAS, ESR2
42dexamethasone43 49 28 1211.1ESR2, VEGFA, CYP19A1, PGR, FAS, AKT1
43genistein43 28 59 2 24 1213.1AKT1, FAS, ESR1, ESR2, PGR, VEGFA
44tamoxifen43 49 28 1211.1PGR, VEGFA, CYP19A1, ESR2, ESR1, BAX
45cycloheximide438.1BIRC5, BAX, AKT1, BCL2, PGR, FAS
46paraffin437.9BAX, BIRC5, BCL2, AKT1, FAS, MUC16
47vegf437.9VEGFA, AKT1, PGR, BCL2, MUC16, ESR1
48estrogen437.9VEGFA, CYP19A1, MUC16, ESR2, PGR, ESR1
49paclitaxel43 49 129.9MUC16, BAX, BIRC5, BCL2, AKT1, FAS
50doxorubicin43 49 129.6CYP19A1, BAX, ESR2, BIRC5, BCL2, FAS

GO Terms for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section

Cellular components related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1pore complexGO:00469309.8BAX, BCL2
2mitochondrial outer membraneGO:00057419.3PGR, BCL2, BAX
3nucleoplasmGO:00056548.2AKT1, PGR, NANOG, ESR2, ESR1, ZNF217
4nucleusGO:00056347.1USP2, BIRC5, BCL2, AKT1, FAS, ESR1

Biological processes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 43)
idNameGO IDScoreTop Affiliating Genes
1activation-induced cell death of T cellsGO:000692410.4AKT1, FAS
2transformed cell apoptotic processGO:000692710.3FAS, BAX
3regulation of nitrogen utilizationGO:000680810.3BAX, BCL2
4uterus developmentGO:006006510.3ESR2, ESR1
5regulation of protein heterodimerization activityGO:004349710.3BCL2, BAX
6positive regulation of extrinsic apoptotic signaling pathway in absence of ligandGO:0200124110.3BAX, FAS
7regulation of protein homodimerization activityGO:004349610.3BCL2, BAX
8endoplasmic reticulum calcium ion homeostasisGO:003246910.3BCL2, BAX
9positive regulation of nitric-oxide synthase activityGO:005100010.3ESR1, AKT1
10response to acidGO:000110110.2BAX, BCL2
11renal system processGO:000301410.2FAS, BCL2
12negative regulation of autophagyGO:001050710.2AKT1, BCL2
13negative regulation of apoptotic signaling pathwayGO:0200123410.2BCL2, BAX
14androgen metabolic processGO:000820910.2CYP19A1, ESR1
15cellular response to organic substanceGO:007131010.2BCL2, BAX
16intracellular estrogen receptor signaling pathwayGO:003052010.2ESR1, ESR2
17apoptotic mitochondrial changesGO:000863710.2BAX, AKT1
18B cell homeostasisGO:000178210.1BCL2, BAX
19positive regulation of blood vessel endothelial cell migrationGO:004353610.1VEGFA, AKT1
20mammary gland alveolus developmentGO:006074910.1VEGFA, ESR1
21vagina developmentGO:006006810.1ESR2, ESR1, BAX
22regulation of mitochondrial membrane potentialGO:005188110.1BAX, BCL2
23intrinsic apoptotic signaling pathwayGO:009719310.0AKT1, BCL2, BAX
24negative regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:004315410.0BIRC5, AKT1, VEGFA
25positive regulation of sequence-specific DNA binding transcription factor activityGO:005109110.0AKT1, ESR1, ESR2
26homeostasis of number of cells within a tissueGO:004887310.0BAX, BCL2
27extrinsic apoptotic signaling pathway via death domain receptorsGO:000862510.0FAS, BCL2, BAX
28extrinsic apoptotic signaling pathway in absence of ligandGO:009719210.0BAX, BCL2, FAS
29intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressGO:007005910.0BCL2, BAX
30response to toxic substanceGO:000963610.0BAX, BCL2, FAS
31release of cytochrome c from mitochondriaGO:00018369.9BAX, BCL2
32positive regulation of peptidyl-serine phosphorylationGO:00331389.9BCL2, AKT1, VEGFA
33cellular response to hypoxiaGO:00714569.9BCL2, AKT1, VEGFA
34response to gamma radiationGO:00103329.9BAX, BCL2
35ovarian follicle developmentGO:00015419.7BAX, BCL2, ESR2, VEGFA
36transcription initiation from RNA polymerase II promoterGO:00063679.6ESR1, ESR2, PGR
37positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathwayGO:019007409.6BCL2, AKT1
38apoptotic processGO:00069159.5FAS, AKT1, BCL2, BIRC5, BAX
39negative regulation of apoptotic processGO:00430669.4VEGFA, FAS, AKT1, BCL2, BIRC5
40signal transductionGO:00071659.4PGR, ESR2, ESR1, FAS, AKT1
41positive regulation of mitotic cell cycleGO:00459319.2BIRC5, NANOG, USP2
42ubiquitin-dependent protein catabolic processGO:00065119.0USP14, USP2, UBE4A
43negative regulation of transcription from RNA polymerase II promoterGO:00001228.3USP2, VEGFA, NANOG, ESR2

Molecular functions related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1estrogen response element bindingGO:003405610.1ESR1, ESR2
2estrogen receptor activityGO:003028410.0ESR2, ESR1
3BH3 domain bindingGO:005143410.0BAX, BCL2
4core promoter sequence-specific DNA bindingGO:00010469.9ESR1, ESR2
5nitric-oxide synthase regulator activityGO:00302359.9AKT1, ESR1
6steroid bindingGO:00054969.8ESR1, ESR2, PGR
7steroid hormone receptor activityGO:00037079.8PGR, ESR2, ESR1
8channel activityGO:00152679.8BAX, BCL2
9enzyme bindingGO:00198999.4PGR, ESR2, ESR1, AKT1, BIRC5
10protein heterodimerization activityGO:00469829.0VEGFA, BCL2, BIRC5, BAX
11identical protein bindingGO:00428028.1BAX, USP2, VEGFA, ESR1, FAS, AKT1
12protein bindingGO:00055155.6ESR1, ESR2, PGR, VEGFA, USP2, USP14

Products for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies
  • Proteins
  • Kits and Assays

Sources for Ovarian Serous Cystadenocarcinoma

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCIt
39NDF-RT
42NINDS
43Novoseek
45OMIM
46OMIM via Orphanet
50PubMed
51QIAGEN
56SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet